Luye Looks To Horizons Beyond Pharma, China
Executive Summary
Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.
You may also be interested in...
Focused China Local Strategy Remains Key Despite Country's Joining ICH – Executives
Top China executives from Pfizer, AstraZeneca, GSK share their views on growing in China amid lingering challenges despite regulatory progress.
Luye Builds China Cancer Diagnosis Capability Via Vela Investment
As a Chinese healthcare player investing money into the oncology treatment market, Luye Group is seeking to stay ahead of the competition by adding disease screening and in vitro diagnostics to its arsenal, via a major investment into Vela Diagnostics of Singapore. As the window of opportunity closes in, the two are working quickly to bring products to the China market.
Waiver Aids Luye’s US Approval Quest For Risperdal Consta Rival
Luye has obtained a Phase III study waiver from the US FDA for its risperidone microsphere product, in a major step towards expediting the filing and potentially first US approval of a value added China-developed drug, which stands to become a rival to J&J’s Risperdal Consta.